Ironwood Pharmaceuticals Presented Final Data From Its Phase 2 STARS Nutrition Program During United European Gastroenterology Week, Evaluating Apraglutide For Short Bowel Syndrome With Intestinal Failure And Colon-in-continuity
Portfolio Pulse from Benzinga Newsdesk
Ironwood Pharmaceuticals presented final data from its Phase 2 STARS Nutrition Program during United European Gastroenterology Week. The data evaluated Apraglutide for Short Bowel Syndrome with Intestinal Failure and Colon-in-continuity, showing a 50% reduction of parenteral support (PS) volume, 100% of patients were clinical responders, and 78% of patients achieved one or more days off PS.
October 16, 2023 | 10:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ironwood Pharmaceuticals' Phase 2 STARS Nutrition Program data shows promising results for Apraglutide in treating Short Bowel Syndrome, which could potentially lead to increased demand for the drug.
The positive results from the Phase 2 STARS Nutrition Program indicate that Apraglutide could be an effective treatment for Short Bowel Syndrome. This could potentially lead to increased demand for the drug, which would positively impact Ironwood Pharmaceuticals' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100